211 related articles for article (PubMed ID: 14755019)
1. The evolving role of epoetin alfa in cancer therapy.
Henry DH
Oncologist; 2004; 9(1):97-107. PubMed ID: 14755019
[TBL] [Abstract][Full Text] [Related]
2. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Campos SM; Duh MS; Lefebvre P; Rosberg J
J Natl Compr Canc Netw; 2005 Nov; 3(6):807-16. PubMed ID: 16316616
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update.
Henry DH
Expert Opin Pharmacother; 2005 Feb; 6(2):295-310. PubMed ID: 15757425
[TBL] [Abstract][Full Text] [Related]
6. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
7. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
8. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
9. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
[TBL] [Abstract][Full Text] [Related]
10. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
Patton J; Reeves T; Wallace J
Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
[TBL] [Abstract][Full Text] [Related]
12. Novel approaches to anemia associated with cancer and chemotherapy.
Kolesar JM
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.
Provenzano R; Garcia-Mayol L; Suchinda P; Von Hartitzsch B; Woollen SB; Zabaneh R; Fink JC;
Clin Nephrol; 2004 Jun; 61(6):392-405. PubMed ID: 15224803
[TBL] [Abstract][Full Text] [Related]
14. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV
Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073
[TBL] [Abstract][Full Text] [Related]
15. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
Adamson JW; Ludwig H
Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
17. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
[TBL] [Abstract][Full Text] [Related]
18. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.
Oberhoff C
Support Care Cancer; 2007 Jun; 15(6):603-611. PubMed ID: 17277926
[TBL] [Abstract][Full Text] [Related]
19. Management of cancer-related anemia: epoetin alfa and quality of life.
Soignet S
Semin Hematol; 2000 Oct; 37(4 Suppl 6):9-13. PubMed ID: 11068950
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]